

Product Data Sheet

Name: Exenatide Acetate

Cat# PP-1250-25 Size: 25 mg

Cat# PP-1250 Size: 100 mg

Description: His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-

Lys-Asn-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2; MW: 4186.03]

Formula C184H282N50O60S

Size: 0.5 mg

Purity: >95%

Appearance: white powder

Store: Desiccated at -20oC.

Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. Exenatide is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster in 1992. It displays biological properties similar to human glucagon-like peptide-1 (GLP-1), a regulator of glucose metabolism and insulin secretion. Exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying.

Exenatide is a 39-amino-acid peptide, an insulin secretagogue, with glucoregulatory effects. Commercial exenatide is produced by direct chemical synthesis. Exendin-4 shares extensive homology and function with mammalian GLP-1, but has a therapeutic advantage in its resistance to degradation by DPP-IV (which breaks down GLP-1 in mammals) therefore allowing for a longer pharmacological half life.

References: Ding X (2006) Hepatology 43 (1): 173–81; Heine RJ (2005) *Ann Intern Med* **143** (8): 559–69; Lee YS (2007) *Diabetes* **56** (6): 1671–1679

Relate Items

Catalog# ProdDescription
PP-1250 Exenatide Acetate (Exendin-4)
PP-1250-25 Exenatide Acetate (Exendin-4)

RP-1481 Exenatide

SP-100297-5 Exendin 4 (1-8) (AA: His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-NH2) (MW: 833.86)

SP-101099-1 Exendin 4 (3-39) (AA: Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2) (MW: 3991.5)

SP-52143-1 Exendin-4 [H-His-Gly-Gly-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-NH2; MW: 4186.03]

SP-55285-1 Exendin (9-39) [H-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-lle-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2; MW: 3369.83]

SP-87196-1 Exendin 4 (3-39) (AA:Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2) (MW: 3992.47)

PP-1250-Excenatide-Acetate 150706A